A Risk Benefit Assessment of Drugs Used in the Treatment of Endometriosis

Summary Medical treatments of endometriosis rely upon the hormonal dependence of endometriotic implants for further growth and extension. The cyclic nature of the symptoms means they may be helped by agents that suppress menstruation both from the endometrium and within the endometriotic lesions. In comparative trials, progestogens have been shown to achieve a similar reduction in symptoms and to induce regression of deposits, but to date there are few long term follow-up data concerning gestrinone. The recent introduction of gonadotrophin-releasing hormone (GnRH) agonists, highly effective at inducing a state of sustained hypoestrogenaemia, is providing another group of compounds suitable for use in the treatment of endometriosis. In comparative trials with danazol, a number of these compounds administered in novel formulations (as intranasal sprays or sustained release depots), have been shown to significantly reduce symptoms both during treatment and for 6 to 12 months post-treatment when compared with baseline. In addition, there are highly significant reductions in revised American Fertility Society (R-AFS) total and implant alone scores following 6 months’ therapy. Whilst these changes are not significantly different from danazol, there are fewer patients discontinuing treatment with GnRH agonists than with danazol. The low circulating levels of 17β-estradiol seen during GnRH analogue therapy result in alterations of bone mineral metabolism similar to those observed at the menopause. Continued prolonged use would thus result in reduced bone mass, and this factor will limit the duration of use of GnRH agonists long term until appropriate combination (‘add-back’) regimens to protect bone are developed. Similar content being viewed by others References Yikorkala O, Viinikka L. Prostaglandins and endometriosis. Acta Obstet Gynaecol Scand 1983; 113 Suppl.: 105–7 Kauppila A, Puolakka J, Yikorkala O. Prostaglandin biosynthesis inhibitors and endometriosis. Prostaglandins 1979; 18: 655–61 Schweppe K-W, Wynn RM, Beller FK. Ultrastructural comparison of endometriotic implants and eutopic endometrium. Am J Obstet Gynecol 1984; 148: 1024–39 Andrews WC, Larsen GD. Endometriosis treatment with hormonal pseudopregnancy and/or operation. Am J Obstet Gynecol 1974; 118: 643–51 Noble AD, Letchworth AT. Tretament of endometriosis: a study of medical management. Br J Obstet Gynaecol 1980; 87: 726–8 Telimaa S, Puolakka J, Ronnberg K, et al. Placebo controlled comparison of danazol and high dose medroxyprogesterone acetate in the treatment of endometriosis. Gynaecol Endocrinol 1987; 1: 13–23 Kauppila AS, Isomaa U, Ronnberg L, et al. Effects of gestrinone in endometriosis tissue and endometrium. Fertil Steril 1985; 44: 466–70 Fedele L, Bianchi S, Viezzoli T, et al. Gestinone versus danazol in the treatment of endometriosis. Fertil Steril 1989; 57: 781–5 Dmowski WP, Headley S, Radwanska E. Effects of danazol on pulsatile gonadotrophin patterns and on serum estradiol levels in normally cycling women. Fertil Steril 1983; 39: 49–55 Dmowski WP, Steele RW, Baker GF. Deficient cellular immunity in endometriosis. Am J Obstet Gynecol 1981; 141: 377–83 Dmowski WP, Kapetanakis E, Scommegna A. Variable effects of danazol on endometriosis at 4 low-dose levels. Obstet Gynecol 1982; 59: 408–15 Barbieri RL, Evans S, Kistner RW. Danazol in the treatment of endometriosis: analysis of 100 cases with 4 year follow-up. Fertil Steril 1982; 37: 737–46 Dmowski WP, Cohen MR. Treatment of endometriosis with an antigonadotrophin, danazol: a laparoscopic and histologic evaluation. Obstet Gynecol 1975; 46: 147–54 Bergquist C. Effects of nafarelin versus danazol on lipids and calcium metabolism. Am J Obstet Gynecol 1990; 162: 589–91 Holland FJ, Fishman L, Costigan DC. Pharmacokinetic characteristics of the gonadotrophin-releasing hormone analog D-Ser (TBU)-EA-luteinising hormone-releasing hormone (buserelin) after subcutaneous and intranasal administration in children with central precocious puberty. J Clin Endocrinol Metab 1986; 63: 1065–70 Chan RL, Henzl MR, LePage ME. Absorption and metabolism of naferelin, a potent agonist of gonadotrophin-releasing hormone. Clin Pharmacol Ther 1988; 44: 275–82 Happ J, Scholteib H, Jacobi GH. Pharmacodynamics, pharmacokinetics and bioavailability of the prolonged LH-RH agonist decapeptyl-SR. In: Klijn JMG et al., editors. Hormonal manipulation of cancer, peptides, growth factors and new (anti) steroidal agents. New York: Raven Press, 1987: 249–53 Clayton RN, Bailey LC, Cottam J. A radioimmunoassay for GnRH agonists analogue in serum patients with prostate cancer treated with D-Ser (TBu) AZA Gly GnRH. Clin Endocrinol 1985; 22: 453–62 Shaw RW. GnRH analogs in the treatment of endometriosis — rationale and efficacy. In: Thomas E, Rock J, editors. Modern approaches to endometriosis. London: Kluwer Academic Publishers, 1991: 257–74 Shaw RW. An open randomised comparitive study of the effect of goserelin depot and danazol in the treatment of endometriosis. Fertil Steril 1992; 58: 265–72 Henzl MR, Gordon SL, Moghissi K, et al. Administration of nasal nafarelin as compared with oral danazol for endometriosis. N Engl J Med 1988; 318: 485–9 The Nafarelin European Endometriosis Group. A large scale danazol controlled trial of efficacy and safety with one year follow-up. Fertil Steril 1992; 57: 514–22 Protocol 310 Study Group. A comparison of the efficacy and safety of buserelin vs. danazol in the treatment of endometriosis. In: Chadha DR, Buttram Jr VC, editors. Current concepts in endometriosis. New York: Alan R. Liss Inc., 1990: 253–67 American Fertility Society. Revised American Fertility Society classification of endometriosis. Fertil Steril 1985; 43: 351–2 Doberl A, Berquist A, Jeppson S, et al. Regression of endometriosis following shorter treatment with, or lower dose of danazol. Acta Obstet Gynaecol Scand 1984; 123 Suppl.: 51–8 Donnez J, Nisolle M, Clerckx F. Evaluation of preoperative use of danazol, gestrinone, lynestrenol, buserelin spray and buserelin implant in the treatment of endometriosis associated infertility. In: Chadha DR, Buttram Jr VC, editors. Current concepts in endometriosis. New York: Alan R. Liss, Inc., 1990: 357–82 Rock JA, Truglia JA, Caplan RJ. The Zoladex Endometriosis Study Group. Zoladex (goserelin acetate implant) in the treatment of endometriosis: a randomised comparison with danazol. Obstet Gynecol 1993; 82: 198–205 Matta WH, Shaw RW, Hesp R, et al. Reversible trabecular bone density loss following induced hypo-oestrogenism with the GnRH analogue buserelin in premenopausal women. Clin Endocrinol 1988; 29: 45–51 Tummon IS, Radwanska E, Ali A. Bone mineral density in women with endometriosis and during ovarian suppression with gonadotrophin-releasing hormone agonists or danazol. Fertil Steril 1988; 49: 792–6 Hayslip CC, Klein TA, Wray HL, et al. The effect of lactation on bone mineral content in healthy postpartum women. Obstet Gynecol 1989; 73: 588–92 Author information Authors and Affiliations Rights and permissions About this article Cite this article Shaw, R.W. A Risk Benefit Assessment of Drugs Used in the Treatment of Endometriosis. Drug-Safety 11, 104–113 (1994). https://doi.org/10.2165/00002018-199411020-00005 Published: Issue date: DOI: https://doi.org/10.2165/00002018-199411020-00005